| Israel | Turkey | Austria | |
| Robotic da Vinci prostatectomy | from $24,570 | from $17,000 | from $20,000 |
| Prostatectomy | from $18,800 | from $6,340 | from $17,000 |
| Nephrectomy | from $22,500 | from $10,000 | from $22,000 |
| NanoKnife | from $18,500 | from $9,500 | from $25,000 |
| Microsurgical intervention for Varicocele | from $5,600 | from $1,700 | from $2,500 |
No hidden fees – just official clinic prices. Pay at the clinic for Urology treatment upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Urology treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Urology treatment journey.
Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.
He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.
He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.
Dr. Barak Rosenzweig, MD, directs the Urological Oncology Service at Sheba Medical Center. He is a uro-oncologic surgeon with nearly 20 years of experience. He treats complex urologic cancers with advanced robotic and minimally invasive methods. He is listed among Israel’s Best Doctors by Forbes.
Expertise includes tumors of the prostate, kidney, bladder, testis, and upper urinary tract. He performs robotic radical prostatectomy, kidney-sparing partial nephrectomy, and advanced laparoscopy. Diagnostics include MRI-guided fusion biopsy and imaging-based personalized planning.
He completed a Urological Oncology fellowship at Memorial Sloan Kettering Cancer Center. He is a Senior Physician in the Department of Urology and a Clinical Senior Lecturer at Tel Aviv University. He is a graduate of the Sheba Talpiot program. He is an active researcher with over 200 publications in urologic oncology.
Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.
He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.
Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.
Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.
He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.
Written by Mariia Mytrofankina
Written by Mariia Mytrofankina
Written by Olena Sikoza